Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0563, Medical Science Bldg. (MSB), Rm 7409, Cincinnati, OH 45267-0563, USA.
Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0563, Medical Science Bldg. (MSB), Rm 7409, Cincinnati, OH 45267-0563, USA; Allergy Partners of Central Indiana, 7430 N Shadeland Ave, Suite 150, Indianapolis, IN 46250, USA.
Immunol Allergy Clin North Am. 2022 Feb;42(1):105-119. doi: 10.1016/j.iac.2021.09.012.
Subcutaneous allergen immunotherapy (SCIT) is a proven treatment of allergic rhinitis, asthma, atopic dermatitis, and prevention of Hymenoptera venom anaphylaxis. The known benefit of SCIT, however, must be considered in each patient relative to the potential risks of systemic allergic reactions (SRs). A mean of 1 SR per 1000 injection visits (0.1%) was estimated to occur between 2008 and 2018. Life-threatening anaphylactic events are estimated to occur in 1/160,000 injection visits. The factors that contribute to SRs and fatal reactions (FRs) are reviewed. Risk management strategies are proposed to prevent and decrease future SCIT associated with SRs, anaphylaxis, and FR.
皮下变应原免疫治疗（SCIT）是一种已被证实的治疗变应性鼻炎、哮喘、特应性皮炎和预防蜂类毒液过敏反应的方法。然而，在考虑 SCIT 的已知益处时，必须考虑到全身性过敏反应（SRs）的潜在风险。据估计，2008 年至 2018 年间，每 1000 次注射就诊中会发生 1 次 SR（0.1%）。预计每 160000 次注射就诊中会发生危及生命的过敏性事件。本文综述了导致 SRs 和致命反应（FRs）的因素。提出了风险管理策略，以预防和减少未来与 SRs、过敏反应和 FR 相关的 SCIT。
